Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) is now available.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has released its unaudited first quarterly report for 2026, covering the three months ended 31 March 2026 and prepared under PRC Accounting Standards for Business Enterprises. The announcement, issued in compliance with Hong Kong listing and securities regulations, confirms board and senior management responsibility for the accuracy and completeness of the disclosed financial information.
The board states that the report contains no false or misleading statements or material omissions, and key executives, including the chairman and chief financial officer, formally vouch for the reliability of the data. While the financial figures themselves are not detailed in the announcement, the filing underscores the company’s adherence to disclosure rules and governance standards expected of issuers on the Hong Kong Stock Exchange.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a Hong Kong-listed healthcare group operating in the pharmaceutical and medical industry. The company, incorporated in the People’s Republic of China as a joint stock company with limited liability, manages its business through a group structure focused on drug development, production and related healthcare services.
Average Trading Volume: 2,600,794
Technical Sentiment Signal: Sell
Current Market Cap: HK$72.71B
For a thorough assessment of 2196 stock, go to TipRanks’ Stock Analysis page.